Elsevier eBooks, Journal Year: 2024, Volume and Issue: unknown, P. 211 - 235
Published: Oct. 25, 2024
Cell investigation., Journal Year: 2025, Volume and Issue: 1(1), P. 100007 - 100007
Published: Jan. 30, 2025
Language: Английский
Citations
4
Biology, Journal Year: 2024, Volume and Issue: 13(10), P. 762 - 762
Published: Sept. 25, 2024
Prostate cancer remains a significant health challenge, being the most prevalent non-cutaneous in men worldwide. This review discusses critical advancements biomarker discovery using single-omics and multi-omics approaches. Multi-omics, integrating genomic, transcriptomic, proteomic, metabolomic, epigenomic data, offers comprehensive understanding of molecular heterogeneity prostate cancer, leading to identification novel biomarkers therapeutic targets. holistic approach not only enhances specificity sensitivity detection but also supports development personalized treatment strategies. Key studies highlighted include genes, genetic mutations, peptides, metabolites, potential through analyses, which have shown promise improving management. The integration clinical practice can potentially revolutionize prognosis treatment, paving way for precision medicine. underscores importance continued research application overcome current challenges diagnosis therapy.
Language: Английский
Citations
4
Bioengineering, Journal Year: 2025, Volume and Issue: 12(3), P. 219 - 219
Published: Feb. 21, 2025
Background: Pheochromocytoma and paragangliomas (PPGLs) caused refractory hypertension in clinics. The sustained risk of local or metastatic recurrences new tumor development prompted more research on diagnosis, prognosis prediction, immunotherapy. Method: stemness is closely related to the heterogeneous growth tumor, metastasis, drug-resistance, mRNA expression-based indices (mRNAsi) could reflect stemness. This was calculated based OCLR machine learning algorithm PPGLs patients’ TCGA RNAseq data. relationship between clinical, molecular, microenvironment (TME) features analyzed through hub genes that best captured stem cell characteristics using weighted gene co-expression network analysis (WGCNA), Cox, LASSO regression analysis. Results: Our study found had higher mRNAsi scores, suggesting degree affect metastasis progression. HRAS, CSDE1, NF1, RET, VHL-mutant subtypes displayed significant difference expression. Patients were divided into high-score low-score subtypes. High-score unfavorable compared with low-score, associated their immune-suppressive features, manifested as low macrophages M1 infiltration downregulated expression immune checkpoints. Furthermore, from viewpoint we established a reliable prognostic for PPGLs, which has highest AUC value (0.908) field so far. And this stratify patients high-risk low-risk subtypes, showing differences prognosis, underlying mechanisms correlated specific molecular alterations, biological processes activation, TME. Notably, high neoantigen further resulted responsive Conclusion: We indicated act potential biomarker integrated multi-data sources, valuable stemness-related genes, developed verified novel scoring system predict guide choice treatment strategies.
Language: Английский
Citations
0
Briefings in Bioinformatics, Journal Year: 2024, Volume and Issue: 25(4)
Published: May 21, 2024
Abstract Recent advances in tumor molecular subtyping have revolutionized precision oncology, offering novel avenues for patient-specific treatment strategies. However, a comprehensive and independent comparison of these methodologies remains unexplored. This study introduces ‘Themis’ (Tumor HEterogeneity analysis on Molecular subtypIng System), an evaluation platform that encapsulates few representative methods, including Stemness, Anoikis, Metabolism, pathway-based classifications, utilizing 38 test datasets curated from The Cancer Genome Atlas (TCGA) significant studies. Our self-designed quantitative uncovers the relative strengths, limitations, applicability each method different clinical contexts. Crucially, Themis serves as vital tool identifying most appropriate methods specific scenarios. It also guides fine-tuning existing to achieve more accurate phenotype-associated results. To demonstrate practical utility, we apply breast cancer dataset, showcasing its efficacy selecting suitable personalized medicine various bridges crucial gap research lays foundation future advancements individualized therapy patient management.
Language: Английский
Citations
2
Cureus, Journal Year: 2024, Volume and Issue: unknown
Published: Sept. 13, 2024
Objectives Microsatellite instability-high (MSI-H) and high tumor mutation burden (TMB-high) frequencies were investigated to determine the efficacy adverse events of pembrolizumab in patients with urologic malignancies (or their equivalents) for which immune checkpoint inhibitors (ICIs) are not covered by Japanese insurance. Methods Between February 2019 April 2024, treated our department whom ICIs approved insurance screened an MSI companion diagnostic kit or comprehensive genomic profiling (CGP). The therapy, presence events, outcomes evaluated retrospectively MSI-H TMB-high. Results In total, 44 tested, median age at testing was 70 years. Castration-resistant prostate cancer (CRPC) most common (n = 31). Overall, 49 tests performed, including 22 kits 27 CGP tests. Of tests, 1 detected MSI-H, 2 TMB-high, simultaneous MSI-H/TMB-high, detection rates 4.1% 11.1% respectively. A patient CRPC neuroendocrine differentiation achieved a complete response prolonged duration without events. shorter simultaneously MSI-H/TMB-high had discontinue early due immune-related Conclusions Despite potential benefit pembrolizumab, TMB-high less frequently
Language: Английский
Citations
1
Trends in cancer, Journal Year: 2024, Volume and Issue: 10(9), P. 825 - 841
Published: July 24, 2024
Metastatic hormone-naïve prostate cancer (mHNPC) is often the initial form of presentation for metastatic and encompasses a heterogeneous patient population with high inter-patient heterogeneity in prognosis response to therapy. A more precise treatment mHNPC, guided by evidence-based biomarkers, remains an unmet medical need. In addition, limited number representative laboratory models mHNPC hampers translation basic research into clinical applications. We provide comprehensive overview biological features that characterize highlight molecular data could explain unique prognostic characteristics identify key open questions.
Language: Английский
Citations
0
Elsevier eBooks, Journal Year: 2024, Volume and Issue: unknown, P. 211 - 235
Published: Oct. 25, 2024
Citations
0